Day – Page 27 – Communicable Diseases Research

Therapeutic response to corticosteroids in a critically ill patient with COVID-19 A case report

4900

Published on 2020-07-312022-10-30
Journal: Medicine [Category] COVID-19, SARS,

The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-07-142022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 48 hour addition Administered adverse effect allergy Alpha anticipated assumed baseline blinded to treatment block clinical Clinical outcome Comorbidity COVID-19 data management Day death determine dissemination drug interaction element eligible eligible participant enrolment evaluate evaluated excluded expected group hospital hospitalised hospitalised patient Hydroxychloroquine independent Intensive intensive care Intervention intervention arms invasive investigator investigator-initiated Laboratory Lopinavir management men New no interaction non-invasive ventilation nucleic acid number objective Open-label outcome participant Patient platform Primary outcome proportion Proportion of participant protocol provided QTC prolongation randomisation randomised randomised controlled trial receive receiving recruited reduce Registered registry representing required researcher Respiratory Support risk Ritonavir Sample size SARS-CoV-2 SARS-COV-2 infection secondary outcome sequence significance level Standard of care status stratified study drug Study protocol Tablet total sample size treated Trial two-sided unblinding ventilatory support Virological website women
[DOI] 10.1186/s13063-020-04576-9 PMC 바로가기 [Article Type] Letter

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-07-132022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hour 48 hour Activation acute lung injury acute pneumonia acute respiratory distress syndrome Administered Adult age all-cause mortality Amendment antibodies antibody Antibody test anticipated antiviral therapy approval ARDS assessment assigned baseline Biomarker Blood cardiac disease Care change class Clinical improvement clinical study clinical trial complement Complement inhibitor component Computed tomography concealed Concentration conducted Confirmed Controlled coronary syndrome COVID-19 criteria current Day diagnosis of SARS-CoV-2 dialysis discharge dissemination dose Duration Efficacy element eligibility Endotracheal intubation EU Clinical Trial EudraCT evaluate the effect expected failure female patient Final fraction France Germany greater half-live hospital Hospitalization humanized Hypercoagulable state Immunoglobulin Infection Inflammatory inhibitor initiated intensive care Intubated intubation invasive Invasive mechanical ventilation investigator IVIG Japan Lung injury mechanical ventilation medication monoclonal multicenter Neisseria meningitidis Non-invasive number objective Open-label original outcome oxygen participant Patient patients randomized patients with COVID-19 Period peripheral capillary phase Placebo Pneumonia polymerase chain positive airway pressure presenting progression protocol randomised randomised controlled trial randomization randomization list Randomized randomized controlled study Randomly Ravulizumab receive recruitment registry Remdesivir renal respiratory respiratory distress Respiratory distress syndrome routine clinical care Safety screened Screening secondary Serious Adverse Events serum severe acute respiratory distress syndrome coronavirus 2 Severe acute respiratory syndrome severe COVID-19 severe pneumonia SOFA Spain SpO2 Sponsor stratified Study protocol supportive care survival The United States therapy time Treatment treatment-emergent adverse event Ultomiris United Kingdom ventricular Viral website with COVID-19 X-ray
[DOI] 10.1186/s13063-020-04548-z PMC 바로가기 [Article Type] Letter

Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients – mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial

ICu 전 환자의 Covid-19에 대한 용도 변경 면역조절 약물 - Covid-19로 입원한 ICu 전 환자에 대한 다중 암 치료 연구 – 용도 변경 약물(TACTIC-R): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-07-082022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] Administered Admission age Analysis Arm ARMS balloon pump balloon pump) Baricitinib baseline blinded Blinding calculated Cambridge Cambridge University Hospitals NHS Foundation Trust can not candidate cardiac clearance clinical picture college comparator comparison Complete COVID-19 infection creatinine creatinine clearance CRP Data analysis Data monitoring committee Day death defined determine diabetes Diagnosis discharge disease dissemination dose drug Drug evaluation Efficacy element enrolled envelope EU Clinical Trial EU Clinical Trials EudraCT event exclusion criteria feature fixed foundation Gault Gender hypertension IDMC immunomodulatory immunomodulatory drug immunomodulatory drugs Immunomodulatory therapies immunomodulatory therapy incidence include Inclusion independent data monitoring committee initial Inotropes interim analysis Intervention intravenously Invasive mechanical ventilation investigator ISRCTN late stage Local male membrane neutrophil Neutrophils NHS number objective on admission once daily Open-label open-label trial opinion Organ failure organ support outcome Oxygenation participant Patient phase Platform trial positive positive COVID-19 predicted Primary outcome progression Prophylaxis protocol Radiographic radiological randomisation randomised randomised controlled trial Ravulizumab recruited recruitment reduce reduced regimen Registered related disease renal renal failure Repurposed drugs risk Sample size scalability selected severity SOC stage 2 Standard of care status stratified Study protocol subject Support Toxicity treatment arm Trial Trial registration triggered Trust university university hospital Venous Thromboembolism website
[DOI] 10.1186/s13063-020-04535-4 PMC 바로가기 [Article Type] Letter

ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-07-022022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] active treatment phase Amiodarone anticipated Arm ARMS assessment baseline blinded Block randomisation block size Blood Group Breastfeeding Cambridge Care Chemoprophylaxis Chloroquine Chronic kidney disease ciprofloxacin clarithromycin clinical clinical testing Compliance Contact coronavirus disease COVID-19 COVID-19 case COVID-19 disease COVID-19 disease severity COVID-19 infection COVID-19 patients criteria current cyclosporin Daily Daily-dosing Date Day deficiency defined described determine diagnosed with COVID-19 Diagnosis digoxin disease dissemination dose dosed element enrolled enrolment epilepsy EU Clinical Trial EudraCT evaluated Factor File fluconazole Follow-up foundation frontline healthcare workers G6PD Genetic Glucose-6-phosphate halofantrine HCQ healthcare Healthcare workers heart failure hospital Hydroxychloroquine hypersensitivity reaction increase Infection Intervention investigator Laboratory Liver disease maintenance Matched mefloquine moxifloxacin National Health Service NHS number objective oral outcome participant Participants Patient patients with COVID-19 pharmacokinetic phase Placebo placebo tablet placebo-controlled trial porphyria positive COVID-19 positive individual Positive test Praziquantel predicted Prevent problem prochlorperazine protocol randomised randomised controlled trial recruited recruitment regimen Registered reported Research Retinal disease Sample size Secondary objective serology serum biomarker Standard statistical analysis status Stratification stratified Study protocol susceptibility symptoms onset syndrome table Tablet tablets time Treatment treatment period Trial Trust university Variation website Weekly Weekly-dosing work
[DOI] 10.1186/s13063-020-04543-4 PMC 바로가기 [Article Type] Letter

Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol

Letter

Published on 2020-06-262022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 24 hour Administered airway allocation concealment Alpha ambient analysed aneurysms Anticoagulant treatment anticoagulation antiplatelet Arm arterial assigned Atrial fibrillation bleeding bleeding event block size Blood BMI Body Breastfeeding breath calculated Cancer clinical clinically Coagulopathy Concomitant conjunctival Continuous contributed Control control group Controlled trial corpus COVID-19 COVID19 criteria Critical D-dimer D-dimer level Day death defined detect diagnostic discharged disease severity dissemination dosage dose effective Efficacy and safety element enoxaparin Epistaxis EudraCT event events expected fibrinogen level gingival bleeding group Haemoglobin haemoptysis health-care hematemesis hematoma hemodynamic heparin High dose high risk history hospital discharge Hospital stay hospitalized patient hypersensitivity Hypothesis IL-6 Impaired impairing improvement IMV In-hospital indication initiated Inpatient INR internal Intervention intervention group Intra-articular intramuscular invasive Invasive mechanical ventilation involved Italian Italy laboratory parameter LMWH low dose low-molecular weight heparin macroscopic Major major bleeding management Mechanical mechanical ventilation medical intervention Medicine Modena NIV Non-invasive number objective occur Occurrence open label ophthalmic oral anticoagulant outcome oxygen paO2/fiO2 parallel group participant pathology Patient performed Pharyngeal swab plasma Platelet Pneumonia positive pregnancy test Presence pressure Primary outcome prophylactic dose prosthetic protocol random randomisation randomised randomised controlled randomised controlled trial randomization Rate receiving recorded recruited Rectal Bleeding reduce reduction in Registered renal function reported required respiratory risk risk of death Sample size SARS-CoV-2 secondary secure Severe COVID-19 pneumonia severe disease significantly Spontaneous standard oxygen therapy Stata status stratified stroke study drug Study protocol subcutaneously surgical susceptible symptomatic syndrome therapeutic dose therapy thrombocytopenia time transfusion Treatment unfractionated heparin unit Vascular venipuncture Venous Thromboembolism web-based system website weight Withdrawal worsening
[DOI] 10.1186/s13063-020-04475-z PMC 바로가기 [Article Type] Letter

A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial”

Letter

Published on 2020-06-262022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Acute respiratory failure Administered Admission Adverse age Aneurysm Antibiotics atherosclerotic baseline blind blood pressure Brain cardiovascular disease carotid cerebrovascular accident cervical spine chronic clinical trial Complete congestive heart failure Consent control group Controlled trial Coronary artery disease cough COVID-19 criteria current cytokine Cytokine storm Day decrease Delay Disabled disease dissemination distress dose electrical element eligible enrolled evaluate expected Follow-up Gender growth Healthcare provider hemorrhage history hospital hospital discharge ICU admission Informed Initiation interleukin interleukin 6 Intervention less mechanical ventilation mechanical ventilator Mild moderate Mortality Myocardial infarction nerve stimulation number O2 Saturation objective occur Older open label outcome oxygen Oxygen level Oxygen therapy parallel group participant Patient patients with moderate per day persist positive prophylactically protocol pulmonary randomisation randomised randomised controlled randomised controlled trial randomization Randomized recruited recruitment reduce reduction regimen Registered required Research respiratory Respiratory failure Sample size Sapphire saturation second dose secondary severity Shortness of breath SOC Spain Standard Standard of care status storm stratified study group Study protocol subject supplemental oxygen supplemental oxygen requirement tested trauma Treatment tumor necrosis factor tumors uncontrolled Vague neurostimulation Valencia Ventilation ventilatory support website women
[DOI] 10.1186/s13063-020-04486-w PMC 바로가기 [Article Type] Letter

How Much Support Is There for the Recommendations Made to the General Population during Confinement? A Study during the First Three Days of the COVID–19 Quarantine in Spain

Article

Published on 2020-06-182022-10-29
Journal: International Journal of Environmental Research an [Category] COVID-19,

Prevalence and Recovery From Olfactory and Gustatory Dysfunctions in Covid-19 Infection: A Prospective Multicenter Study

Original Articles

Published on 2020-06-122022-10-28
Journal: American Journal of Rhinology & Allergy [Category] COVID-19, Fulltext, SARS,

Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-102022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Administered age antibiotic antiviral efficacy Asthma Azithromycin Beta blocker blinded block calcium cardiovascular change changed chronic clinical combination therapy Control control group coordinator COPD COVID-19 COVID-19 test Day days alive death derivative Diagnosis Direct Current discharged disorder dissemination double-blind study ECG element ergot alkaloid expected Final FiO2 generate Glucose glucose-6-phosphate dehydrogenase deficiency guide hearing loss hematological hospital hospitalisation Hospitalization hospitals Hydroxychloroquine hypersensitivity impede Inclusion Informed consent intensive care Interstitial lung disease Intervention intervention group invasive ventilation investigated investigator Liver disease lung maculopathy medication mental illness modulation myasthenia gravis negative pregnancy test network Neurogenic neurological number objective offered outcome parallel group participant Patient patients with COVID-19 Placebo pregnant Primary outcome problem protocol psoriasis pulmonary QTc QTc interval randomisation randomised randomised controlled trial receive recruited recruitment reduce Registered reported respiratory infections retinopathy risk Sample size sequence significantly Sponsor Standard standard care standard treatment status Stratification Study protocol the patient therapy treated Treatment Trial Visual field website women
[DOI] 10.1186/s13063-020-04409-9 PMC 바로가기 [Article Type] Letter